In many ways, the massive fraud perpetuated by blood-testing start-up Theranos could not have happened without the lines between traditional technology VC and health care VC blurring. The writer who first exposed the fraud, WSJ reporter John Carreyrou, joined tech columnist Eric Jhonsa and TheDeal’s senior reporter David Marcus to discuss the breakdowns in due diligence that took place along the way, and its implications for investors.